Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulatory drugs.

Edward Crane1, Alan List

  • 1Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, and University of South Florida College of Medicine, Tampa 33612, USA.

Cancer Investigation
|November 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.

Journal of the American Geriatrics Society·2023
Same author

A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.

Drugs & aging·2023
Same author

Correction to: New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.

Current oncology reports·2022
Same author

New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.

Current oncology reports·2022
Same author

The role of innate immunity in MDS pathogenesis.

HemaSphere·2022
Same author

Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.

Cancer medicine·2020
Same journal

Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System.

Cancer investigation·2026
Same journal

Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications.

Cancer investigation·2026
Same journal

Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.

Cancer investigation·2026
Same journal

The Heterogeneity of B Cells Potentially Contributes to Metastasis of Clear Cell Renal Cell Carcinomas.

Cancer investigation·2026
Same journal

The Association Between Lymphocyte-Monocyte Ratio, Tumor-Infiltrating Lymphocytes, and Tumor-Associated Macrophages with 3-Year Progression-Free Survival in Advanced Local Stage Nasopharyngeal Cancer Patients.

Cancer investigation·2026
Same journal

<i>In Vivo</i> Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles.

Cancer investigation·2026
See all related articles

Thalidomide analogues, lenalidomide and pomalidomide, offer potent immunomodulatory effects for treating cancers like multiple myeloma. These novel drugs show improved safety profiles compared to thalidomide.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Thalidomide, once withdrawn, is now a parent compound for immunomodulatory drugs (IMiDs).
  • Lenalidomide (CC-5013) and pomalidomide (CC-4047) are potent IMiD analogues with improved therapeutic potential.
  • These IMiDs demonstrate enhanced regulation of immune and cytokine responses, with reduced neurotoxicity compared to thalidomide.

Purpose of the Study:

  • To review preclinical data on IMiDs' effects on key biological pathways.
  • To outline the therapeutic evolution of thalidomide and its analogues.
  • To highlight the potential of IMiDs in treating hematologic malignancies.

Main Methods:

  • Review of preclinical data focusing on cytokine modulation (TNF-α, IL-12).
  • Analysis of effects on angiogenesis and T-cell function.

Related Experiment Videos

  • Examination of clinical evolution and therapeutic applications.

    • Main Results:

    • IMiDs exhibit significant modulation of tumor necrosis alpha and interleukin 12.
    • Preclinical studies indicate favorable effects on angiogenesis and T-cell activity.
    • Lenalidomide and pomalidomide show promise in treating multiple myeloma and myelodysplastic syndromes.

    Conclusions:

    • Lenalidomide and pomalidomide represent a significant advancement in immunomodulatory therapy.
    • These IMiDs offer a promising therapeutic window for hematologic cancers.
    • Further clinical evaluation is warranted based on promising preclinical and initial clinical results.